Alpha Centric Advisors LLC Collegium Pharmaceutical, Inc Transaction History

Alpha Centric Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$16.14 - $23.55 $306,660 - $447,450	-19,000 Reduced 27.74%	49,500 $1.15 Million
Q3 2022 Nov 08, 2022	BUY	$15.46 - $20.1 $123,680 - $160,800	8,000 Added 13.22%	68,500 $1.1 Million
Q4 2021 Feb 25, 2022	BUY	$17.5 - $21.35 $411,250 - $501,725	23,500 Added 63.51%	60,500 $1.13 Million
Q3 2021 Mar 09, 2022	BUY	$17.75 - $25.39 $497,000 - $710,920	28,000 Added 311.11%	37,000 $730,000
Q4 2020 Mar 11, 2022	BUY	$17.83 - $22.29 $117,677 - $147,114	6,600 Added 275.0%	9,000 $180,000
Q3 2020 Mar 11, 2022	SELL	$15.78 - $20.82 $11,835 - $15,615	-750 Reduced 23.81%	2,400 $50,000
Q2 2020 Mar 11, 2022	BUY	$15.49 - $23.51 $48,793 - $74,056	3,150 New	3,150 $55,000

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.